IBOV 173,885.34 ▼ 1.52% IPSA 10,879.65 ▼ 0.77% IPC MEX 67,304.62 ▲ 0.18% MERVAL 3,233,105 ▼ 0.71% COLCAP 2,304.68 ▲ 0.15% BVL PERÚ 57,237.60 — — USD/BRL5.12▼ 0.08% USD/MXN17.45▲ 0.09% USD/CLP932.73▲ 0.20% USD/COP3,190▼ 0.43% USD/PEN3.40▼ 0.10% USD/ARS1,495▼ 0.32% USD/UYU40.21▲ 1.46% USD/PYG5,987▲ 0.90% USD/BOB11.70▲ 5.59% USD/DOP58.01▲ 0.02% USD/CRC449.99▲ 1.61% USD/GTQ7.62▲ 2.26% USD/HNL26.76▲ 0.79% USD/NIO36.62▲ 0.31% USD/VES742.37▲ 0.07% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.29▲ 0.41% USD/TTD6.75▲ 1.28% EUR/BRL5.87▲ 0.75% BRENT 90.40 ▲ 7.50% WTI 84.62 ▲ 6.76% IRON ORE 161.91 — — COPPER 6.38 ▲ 0.96% GOLD 4,149 ▲ 2.80% SILVER 58.53 ▲ 2.14% SOY 1,192 ▼ 1.69% CORN 471.00 ▲ 2.73% WHEAT 660.00 ▼ 0.38% COFFEE 326.60 ▼ 3.77% SUGAR 14.50 ▼ 0.34% ORANGE JUICE 137.95 ▲ 0.80% COTTON 79.38 ▲ 0.21% COCOA 5,169 ▼ 0.62% BEEF 224.13 ▼ 1.47% CATTLE 339.05 ▼ 1.17% LITHIUM 66.74 ▼ 0.33% PETR4 42.00 ▲ 1.92% VALE3 75.05 ▼ 0.85% ITUB4 41.82 ▼ 2.43% BBDC4 18.35 ▼ 2.24% ABEV3 15.90 ▼ 1.24% BBAS3 20.78 ▼ 0.24% B3SA3 15.32 ▼ 4.25% WEGE3 45.64 ▼ 2.27% PRIO3 58.41 ▲ 2.89% SUZB3 42.30 ▼ 1.86% RENT3 37.44 ▼ 2.42% AZZA3 16.15 ▼ 5.83% CSAN3 3.89 ▼ 2.75% RAIZ4 0.26 ▼ 3.70% PCAR3 2.81 ▲ 2.55% GMAT3 3.89 ▼ 0.77% PSSA3 53.81 ▼ 2.00% CVCB3 1.28 ▼ 3.03% POSI3 3.55 ▼ 1.39% SLCE3 13.09 ▼ 0.53% NATU3 8.27 ▼ 0.84% BRKM5 5.72 ▼ 4.03% RANI3 7.96 ▼ 2.09% CSNA3 5.20 ▼ 7.80% CMIN3 5.98 ▲ 0.34% USIM5 8.32 ▼ 4.26% GGBR4 24.79 ▼ 1.39% ENEV3 25.87 ▲ 0.08% CPFE3 44.79 ▼ 2.55% CMIG4 11.00 ▼ 1.70% EQTL3 37.82 ▼ 2.60% LREN3 13.36 ▼ 3.88% VIVT3 32.54 ▼ 3.81% RAIL3 13.95 ▼ 0.92% KLABIN 18.02 ▼ 0.11% RAIA DROGASIL 17.76 ▼ 2.42% RDOR3 33.85 ▼ 1.37% HAPV3 10.55 ▼ 0.47% FLRY3 16.83 ▼ 1.35% SMTO3 14.27 ▼ 0.21% UGPA3 32.00 ▼ 1.39% VBBR3 34.60 ▼ 1.51% BBSE3 40.92 ▼ 0.70% BPAC11 54.66 ▼ 2.11% CURY3 28.85 ▼ 4.15% AERI3 2.11 ▲ 0.96% VIVARA 22.35 ▼ 1.15% COMPASS 24.21 ▼ 4.00% VAMOS 3.31 ▼ 0.60% SANB11 25.63 ▼ 7.37% ASAI3 8.30 ▲ 0.73% SBSP3 26.61 ▼ 5.87% WALMEX 49.54 ▲ 1.58% GMEXICO 207.79 ▼ 1.01% FEMSA 211.26 ▼ 5.23% CEMEX 20.51 ▼ 2.10% GFNORTE 197.01 ▼ 1.31% BIMBO 59.96 ▲ 0.10% TELEVISA 9.86 ▲ 0.31% AMX 21.77 ▼ 3.24% GAP 379.85 ▲ 0.56% ASUR 271.97 ▲ 0.29% OMA 233.18 ▼ 0.75% KOF 186.22 ▼ 1.90% GRUMA 267.17 ▼ 0.29% KIMBER 40.44 ▼ 0.49% SQM-B 63,799 ▲ 2.08% COPEC 6,190 ▼ 1.75% BSANTANDER 80.24 ▲ 1.42% FALABELLA 6,216 ▲ 1.88% ENELAM 86.69 ▲ 1.04% CENCOSUD 1,919 ▲ 1.00% CMPC 1,035 ▲ 0.01% BANCO CHILE 191.00 ▲ 1.00% LATAM AIR 24.40 ▼ 2.40% YPF 79,600 ▲ 0.09% GGAL 7,795 ▼ 0.76% PAMPA 5,370 ▼ 1.47% TXAR 658.00 ▼ 1.64% ALUAR 976.00 ▼ 1.21% TGS 9,510 ▲ 0.48% CEPU 2,291 ▼ 1.88% MIRGOR 16,550 ▲ 0.15% COME 42.55 ▲ 0.07% LOMA NEGRA 3,673 ▲ 0.75% BYMA 298.00 ▼ 0.75% TELECOM ARG 4,305 ▼ 0.69% ECOPETROL 16.40 ▲ 3.60% BANCOLOMBIA 89.47 ▲ 0.45% GRUPO AVAL 4.90 ▲ 0.41% CREDICORP 383.93 ▼ 1.29% SOUTHERN COPPER 175.47 ▼ 1.95% BUENAVENTURA 30.21 ▼ 0.56% MERCADOLIBRE 1,863 ▲ 0.04% NUBANK 14.04 ▼ 4.36% XP 16.31 ▼ 2.92% PAGSEGURO 9.54 ▼ 0.73% STONE 10.96 ▼ 1.79% GLOBANT 38.15 ▲ 8.66% TECNOGLASS 44.88 ▼ 4.96% GAP AIRPORT 216.97 ▼ 0.24% ASUR 271.97 ▲ 0.29% OMA AIRPORT 106.38 ▼ 1.75% AMX ADR 24.87 ▼ 3.27% FEMSA ADR 121.06 ▼ 5.22% CEMEX ADR 11.70 ▼ 2.50% PETROBRAS ADR 18.59 ▲ 2.88% VALE ADR 14.65 ▼ 0.34% ITAU ADR 8.15 ▼ 1.93% SANTANDER BR 5.10 ▼ 6.93% AMBEV ADR 3.10 ▼ 0.96% CSN 1.03 ▼ 6.36% GERDAU 4.86 ▼ 1.82% LATAM ADR 52.05 ▼ 2.76% BTC 63,922 ▲ 0.08% ETH 1,906 ▼ 0.73% SOL 73.53 ▼ 0.23% XRP 1.07 ▲ 0.41% BNB 571.16 ▲ 0.12% ADA 0.16 ▲ 0.38% DOGE 0.07 ▼ 0.98% AVAX 6.41 ▼ 2.35% LINK 8.30 ▼ 1.52% DOT 0.76 ▲ 0.14% LTC 45.23 ▼ 1.96% BCH 212.00 ▼ 0.96% TRX 0.33 ▲ 0.31% XLM 0.17 ▼ 1.11% HBAR 0.07 ▼ 0.85% NEAR 1.61 ▼ 2.20% ATOM 1.28 ▼ 1.66% AAVE 96.27 ▼ 4.43% SELIC 14.25% EMBRAER 86.09 ▼ 3.12% EMBRAER ADR 67.66 ▼ 2.07% JBS 14.23 ▲ 2.15% JBS BDR 72.38 ▲ 2.56% MBRF3 16.66 ▲ 2.21% MBRFY 3.18 ▲ 0.95% INTER 5.41 ▼ 3.22% EGX 53,627 ▼ 0.19% USD/ZAR16.66▼ 0.18% USD/NGN1,363▼ 0.17% NIKKEI 61,434 ▼ 1.49% CSI300 4,600 ▲ 0.67% HSI 25,808 ▲ 1.96% NIFTY 24,250 ▲ 1.10% KOSPI 5,663 ▼ 5.98% JCI 6,091 ▼ 0.64% USD/JPY 163.39 — 0.00% USD/CNY6.75▼ 0.25% DAX 25,460 ▼ 0.01% CAC 8,408 ▼ 0.60% FTSE 10,908 ▲ 0.34% MIB 51,443 ▼ 0.49% IBEX 19,413 ▼ 1.59% STOXX 645.01 ▼ 0.29% EUR/USD1.15▲ 0.74% GBP/USD1.34▲ 0.57% SPX 7,316 ▼ 1.52% DJI 51,594 ▼ 2.19% NDX 27,192 ▼ 2.06% RUT 2,906 ▼ 1.61% TSX 35,334 ▼ 1.16% VIX 20.66 ▲ 13.45% USD/CAD1.40▼ 0.47% US10Y 4.6220 ▲ 0.39% IBOV 173,885.34 ▼ 1.52% IPSA 10,879.65 ▼ 0.77% IPC MEX 67,304.62 ▲ 0.18% MERVAL 3,233,105 ▼ 0.71% COLCAP 2,304.68 ▲ 0.15% BVL PERÚ 57,237.60 — — USD/BRL 5.12 ▼ 0.08% USD/MXN 17.45 ▲ 0.09% USD/CLP 932.73 ▲ 0.20% USD/COP 3,190 ▼ 0.43% USD/PEN 3.40 ▼ 0.10% USD/ARS 1,495 ▼ 0.32% USD/UYU 40.21 ▲ 1.46% USD/PYG 5,987 ▲ 0.90% USD/BOB 11.70 ▲ 5.59% USD/DOP 58.01 ▲ 0.02% USD/CRC 449.99 ▲ 1.61% USD/GTQ 7.62 ▲ 2.26% USD/HNL 26.76 ▲ 0.79% USD/NIO 36.62 ▲ 0.31% USD/VES 742.37 ▲ 0.07% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.29 ▲ 0.41% USD/TTD 6.75 ▲ 1.28% EUR/BRL 5.87 ▲ 0.75% BRENT 90.40 ▲ 7.50% WTI 84.62 ▲ 6.76% IRON ORE 161.91 — — COPPER 6.38 ▲ 0.96% GOLD 4,149 ▲ 2.80% SILVER 58.53 ▲ 2.14% SOY 1,192 ▼ 1.69% CORN 471.00 ▲ 2.73% WHEAT 660.00 ▼ 0.38% COFFEE 326.60 ▼ 3.77% SUGAR 14.50 ▼ 0.34% ORANGE JUICE 137.95 ▲ 0.80% COTTON 79.38 ▲ 0.21% COCOA 5,169 ▼ 0.62% BEEF 224.13 ▼ 1.47% CATTLE 339.05 ▼ 1.17% LITHIUM 66.74 ▼ 0.33% PETR4 42.00 ▲ 1.92% VALE3 75.05 ▼ 0.85% ITUB4 41.82 ▼ 2.43% BBDC4 18.35 ▼ 2.24% ABEV3 15.90 ▼ 1.24% BBAS3 20.78 ▼ 0.24% B3SA3 15.32 ▼ 4.25% WEGE3 45.64 ▼ 2.27% PRIO3 58.41 ▲ 2.89% SUZB3 42.30 ▼ 1.86% RENT3 37.44 ▼ 2.42% AZZA3 16.15 ▼ 5.83% CSAN3 3.89 ▼ 2.75% RAIZ4 0.26 ▼ 3.70% PCAR3 2.81 ▲ 2.55% GMAT3 3.89 ▼ 0.77% PSSA3 53.81 ▼ 2.00% CVCB3 1.28 ▼ 3.03% POSI3 3.55 ▼ 1.39% SLCE3 13.09 ▼ 0.53% NATU3 8.27 ▼ 0.84% BRKM5 5.72 ▼ 4.03% RANI3 7.96 ▼ 2.09% CSNA3 5.20 ▼ 7.80% CMIN3 5.98 ▲ 0.34% USIM5 8.32 ▼ 4.26% GGBR4 24.79 ▼ 1.39% ENEV3 25.87 ▲ 0.08% CPFE3 44.79 ▼ 2.55% CMIG4 11.00 ▼ 1.70% EQTL3 37.82 ▼ 2.60% LREN3 13.36 ▼ 3.88% VIVT3 32.54 ▼ 3.81% RAIL3 13.95 ▼ 0.92% KLABIN 18.02 ▼ 0.11% RAIA DROGASIL 17.76 ▼ 2.42% RDOR3 33.85 ▼ 1.37% HAPV3 10.55 ▼ 0.47% FLRY3 16.83 ▼ 1.35% SMTO3 14.27 ▼ 0.21% UGPA3 32.00 ▼ 1.39% VBBR3 34.60 ▼ 1.51% BBSE3 40.92 ▼ 0.70% BPAC11 54.66 ▼ 2.11% CURY3 28.85 ▼ 4.15% AERI3 2.11 ▲ 0.96% VIVARA 22.35 ▼ 1.15% COMPASS 24.21 ▼ 4.00% VAMOS 3.31 ▼ 0.60% SANB11 25.63 ▼ 7.37% ASAI3 8.30 ▲ 0.73% SBSP3 26.61 ▼ 5.87% WALMEX 49.54 ▲ 1.58% GMEXICO 207.79 ▼ 1.01% FEMSA 211.26 ▼ 5.23% CEMEX 20.51 ▼ 2.10% GFNORTE 197.01 ▼ 1.31% BIMBO 59.96 ▲ 0.10% TELEVISA 9.86 ▲ 0.31% AMX 21.77 ▼ 3.24% GAP 379.85 ▲ 0.56% ASUR 271.97 ▲ 0.29% OMA 233.18 ▼ 0.75% KOF 186.22 ▼ 1.90% GRUMA 267.17 ▼ 0.29% KIMBER 40.44 ▼ 0.49% SQM-B 63,799 ▲ 2.08% COPEC 6,190 ▼ 1.75% BSANTANDER 80.24 ▲ 1.42% FALABELLA 6,216 ▲ 1.88% ENELAM 86.69 ▲ 1.04% CENCOSUD 1,919 ▲ 1.00% CMPC 1,035 ▲ 0.01% BANCO CHILE 191.00 ▲ 1.00% LATAM AIR 24.40 ▼ 2.40% YPF 79,600 ▲ 0.09% GGAL 7,795 ▼ 0.76% PAMPA 5,370 ▼ 1.47% TXAR 658.00 ▼ 1.64% ALUAR 976.00 ▼ 1.21% TGS 9,510 ▲ 0.48% CEPU 2,291 ▼ 1.88% MIRGOR 16,550 ▲ 0.15% COME 42.55 ▲ 0.07% LOMA NEGRA 3,673 ▲ 0.75% BYMA 298.00 ▼ 0.75% TELECOM ARG 4,305 ▼ 0.69% ECOPETROL 16.40 ▲ 3.60% BANCOLOMBIA 89.47 ▲ 0.45% GRUPO AVAL 4.90 ▲ 0.41% CREDICORP 383.93 ▼ 1.29% SOUTHERN COPPER 175.47 ▼ 1.95% BUENAVENTURA 30.21 ▼ 0.56% MERCADOLIBRE 1,863 ▲ 0.04% NUBANK 14.04 ▼ 4.36% XP 16.31 ▼ 2.92% PAGSEGURO 9.54 ▼ 0.73% STONE 10.96 ▼ 1.79% GLOBANT 38.15 ▲ 8.66% TECNOGLASS 44.88 ▼ 4.96% GAP AIRPORT 216.97 ▼ 0.24% ASUR 271.97 ▲ 0.29% OMA AIRPORT 106.38 ▼ 1.75% AMX ADR 24.87 ▼ 3.27% FEMSA ADR 121.06 ▼ 5.22% CEMEX ADR 11.70 ▼ 2.50% PETROBRAS ADR 18.59 ▲ 2.88% VALE ADR 14.65 ▼ 0.34% ITAU ADR 8.15 ▼ 1.93% SANTANDER BR 5.10 ▼ 6.93% AMBEV ADR 3.10 ▼ 0.96% CSN 1.03 ▼ 6.36% GERDAU 4.86 ▼ 1.82% LATAM ADR 52.05 ▼ 2.76% BTC 63,922 ▲ 0.08% ETH 1,906 ▼ 0.73% SOL 73.53 ▼ 0.23% XRP 1.07 ▲ 0.41% BNB 571.16 ▲ 0.12% ADA 0.16 ▲ 0.38% DOGE 0.07 ▼ 0.98% AVAX 6.41 ▼ 2.35% LINK 8.30 ▼ 1.52% DOT 0.76 ▲ 0.14% LTC 45.23 ▼ 1.96% BCH 212.00 ▼ 0.96% TRX 0.33 ▲ 0.31% XLM 0.17 ▼ 1.11% HBAR 0.07 ▼ 0.85% NEAR 1.61 ▼ 2.20% ATOM 1.28 ▼ 1.66% AAVE 96.27 ▼ 4.43% SELIC 14.25% EMBRAER 86.09 ▼ 3.12% EMBRAER ADR 67.66 ▼ 2.07% JBS 14.23 ▲ 2.15% JBS BDR 72.38 ▲ 2.56% MBRF3 16.66 ▲ 2.21% MBRFY 3.18 ▲ 0.95% INTER 5.41 ▼ 3.22% EGX 53,627 ▼ 0.19% USD/ZAR 16.66 ▼ 0.08% USD/NGN 1,363 ▲ 0.01% NIKKEI 61,434 ▼ 1.49% CSI300 4,600 ▲ 0.67% HSI 25,808 ▲ 1.96% NIFTY 24,250 ▲ 1.10% KOSPI 5,663 ▼ 5.98% JCI 6,091 ▼ 0.64% USD/JPY 163.39 — 0.00% USD/CNY 6.7544 ▼ 0.10% DAX 25,460 ▼ 0.01% CAC 8,408 ▼ 0.60% FTSE 10,908 ▲ 0.34% MIB 51,443 ▼ 0.49% IBEX 19,413 ▼ 1.59% STOXX 645.01 ▼ 0.29% EUR/USD 1.1474 ▲ 0.69% GBP/USD 1.3370 ▲ 0.58% SPX 7,316 ▼ 1.52% DJI 51,594 ▼ 2.19% NDX 27,192 ▼ 2.06% RUT 2,906 ▼ 1.61% TSX 35,334 ▼ 1.16% VIX 20.66 ▲ 13.45% USD/CAD 1.4036 ▼ 0.03% US10Y 4.6220 ▲ 0.39%
since 2009
Wednesday, July 29, 2026

Covid-19: Prominent Portuguese cardiologist warns of ethical lapses in vaccine policies

By · October 18, 2021 · 7 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

By Teresa Gomes Mota, Cardiologist

RIO DE JANEIRO, BRAZIL – What would the reality of cardiovascular diseases be, the leading cause of death in Portugal and the world, if the media were to dedicate the same amount of time each day as it does to Covid-19?

When I began my professional life as a doctor, I took the Hippocratic oath, which began with “I solemnly vow to consecrate my life to the service of mankind.”

It seemed a bit ambitious to me at the time to imagine that my humble efforts, which would be performed by treating patients on a case-by-case basis, could be considered a service to Humanity.

Teresa Gomes Mota, Cardiologist
Teresa Gomes Mota, Cardiologist. (Photo internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

The current approaches against the Covid-19 pandemic are pushing Humanity and ethical principles over a precipice of very difficult return, with the active involvement of a few doctors and the nihilism or passivity of virtually all the rest, in contradiction to the principles of our profession.

The Portuguese government, like that of most countries in the world, opted early on for a vaccination strategy as the main hope and weapon to fight the SARS-CoV-2 pandemic, a respiratory virus, mutant, as are RNA viruses, belonging to a kind of coronavirus for which no vaccine has previously performed safely and effectively.

The vaccines created in record time and authorized for marketing by the leading international drug agencies, only conditionally (or for emergency use) due to insufficient efficacy and safety data, were rapidly produced and distributed globally.

Read also: Check out our coverage on alternative views on Covid-19

Promoted daily in the media as safe and effective, people were first invited, then coerced and, in some states, forced to take them, with methodologies comparable worldwide: massive dissemination of the purported advantages for individual protection, for group protection, for the defense of the economy, for education, for the return to everyday life; required to secure the digital vaccination certificate, created to allow travel between countries, but whose scope has been extended to access commercial establishments, events (family, sports, cultural, professional), nursing homes, hospitals, schools.

And in some countries, the abuses of citizens’ rights and freedoms have even gone as far as mandatory injections with these vaccines.

But there are several inconsistencies with respect to these vaccines, which present severe shortcomings in proving their scientific premises if combined with all the pressure exerted on people to get them.

Let’s see:

Vaccines are not sterilizing, they do not prevent contagion or transmission. They do not confer group protection, at best, they confer individual protection to individuals at risk for severe disease and death from COVID-19. Vaccine efficacy in antibody titers declines rapidly over time, in months, and new variants contribute to vaccine escape, i.e., vaccine inefficacy.

Vaccine-induced immunity is lower than that conferred by natural infection. The advantages of vaccinating people recovered from SARS-CoV-2 infection, in addition to being scientifically implausible, have not been demonstrated in randomized trials. It is unclear why people who have already had the disease are vaccinated.

The much-heralded safety of vaccines, in the way that a drug’s safety was perceived until 2019, does not exist. These vaccines are particularly deadly, a stain on the history of medicine, which should have already led, in the first two months of their application, to a halt in human vaccination programs until a better scientific explanation of the reasons for the many and varied serious adverse reactions and cases of death that have been reported to drug regulators, namely European and American.

Despite the unprecedented numbers of adverse reactions, there has been no interest from drug authorities in promoting active pharmaco-vigilance, nor in making it mandatory to report deaths occurring in the first 15 days after vaccination, particularly in the most vulnerable groups, such as the elderly and nursing home residents, pregnant women and children. Autopsies of vaccinees, which could help to understand what is going on objectively, are systematically dismissed.

There are no studies on pregnant or nursing mothers, yet health authorities recommend vaccinating these groups as safe and effective.

Covid-19 is benign in children and youths, yet the vaccines, with no long-term safety studies conducted yet, have achieved conditional approval in the US and EU for those over 12 years of age, and upcoming support for children over five years of age is announced.

There are no studies on the interaction of vaccines with other drugs, including vaccines for other diseases, and nevertheless, joint administration with influenza vaccines is being considered; take as an example Portugal, wherein the absence of a recommendation from the European Medicines Agency (EMA), the Directorate General of Health announces that it is waiting for a position from the World Health Organization.

Unlike the additional doses for immunosuppressed patients, the booster doses (third dose) have not been recommended by the EMA due to lack of current evidence of efficacy (which may yet emerge) and limited safety data (a small trial that only included people aged 18 to 55 years). However, the Portuguese health authorities were quick to recommend the booster dose for people over 65.

The vaccines are neither effective nor safe, and yet Portugal, which is among the countries with the world’s highest vaccination rate, in addition to the 15 million doses already administered, will be delivered more than 6 million in 2021 to continue inoculating its population.

Doctors and other health professionals, the leading advocates of people’s s health, are very rarely allowed in the media to challenge the safety and efficacy of vaccines. Suppose they do so in public spaces or on social media. In that case, they are vilified as denialists, obscurantists, advocates of conspiracy theories, and sometimes their accounts are blocked, their articles rejected or unpublished, and they face disciplinary proceedings.

Journalists do not ask the advocates of these biological therapies in experimental stages for everyone’s uncomfortable questions. For over a year and a half, the media has been repeating daily news that spreads fear of the pandemic and optimistic and hopeful messages about vaccines.

By sticking to the official narrative promoted by the political power, day after day, they have managed to convince populations to adhere to vaccination programs despite the many questions of effectiveness and safety that arise. But they haven’t invested time in spreading the word about fundamental lifestyle changes to prevent a poor prognosis when faced with a SARS-CoV-2 infection, such as reducing excess weight or controlling blood pressure, for example.

One cannot help but ask: what particular and intense interest do governments and the media have in promoting vaccination for Covid-19 that has not been previously shown for promoting approaches to highly devastating chronic diseases?

People who have suffered adverse reactions to vaccines and their relatives struggle to share their losses publicly, they may be denialists if they try to or if they organize themselves into patient groups. Pharmaceutical companies are exempt from liability for the harm caused to people by marketing these still experimental drugs.

With honorable exceptions, scientific societies and professional associations have renounced their impartial role of research, scientific validation, monitoring and observing clinical events, medical training, and issuing recommendations to health professionals when they might lead to actions and outcomes against the official pro-vaccine narrative. As far as the pandemic is concerned, for the most part, they sound more like faint echoes of a sound whose origin is indiscernible, which leads one to wonder about potential conflicts of interest.

Doctors who use their minds to study, observe, reflect, decide according to each case and according to their own experience, who, instead of blindly following incongruous norms and with non-existent or dubious scientific bases, follow the Hippocratic principle that features on all cards of the Physicians’ Council – The health of my patient will be my first concern – need to carefully measure their actions and words to avoid being slandered, attacked in their reputation, or having their professional credentials suspended.

For this reason, this article only presents facts that attest to the incoherence of many measures that have been recommended and implemented in the troubled period we are currently experiencing so that each person may draw their conclusions.

But with an even greater conviction than on that day 38 years ago, I reaffirm the oath I took and invite all colleagues to do the same, conscientiously and courageously. Some may prefer the more recent version from which I highlight this excerpt:

“I will not use my knowledge to violate human rights and civil liberties, even under threat.”

Teresa Gomes Mota was born in 1959 in Lisbon. She has a degree in Medicine and a specialty in Cardiology. She was a Cardiology Hospital Consultant at the Pulido Valente Hospital until 2004 and Assistant Professor at the Faculty of Medical Sciences of Lisbon until 2007. She is on the Board of Directors of the Portuguese Foundation of Cardiology.

She is the author of dozens of publications and scientific papers in national and foreign conferences. She has developed and coordinated several cardiovascular preventions and health promotion campaigns with the inclusion of thousands of people.

In addition to many educational texts aimed at the population, she has published: “Do outro lado da bata” (From the other side of the scrubs)- Climepsi 2004; “Emagrecer. Eu consigo!” (Losing weigh. I can do it!) – Asa II Editions 2006 (awarded with the Gourmand World Cookbook Awards 2006 in the Best Nutrition and Health Book category of the Gourmand Portugal Awards). She is a member of several scientific and philosophical societies.

Source:  Observador, Portugal

Join us on Telegram: t.me/theriotimes

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.